Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

This has resulted in major motor and survival benefits.5–7 In the past 7 years, disease-modifying therapies including nusinersen (Spinraza; Biogen, USA), onasemnogene abeparvovec (Zolgensma; Novartis, ...

Biogen appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's ...

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. The Massachusetts-based biotech firm plans to set up shop in an undisclosed office in South San ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Robert F. Kennedy, Jr. discusses the findings of the Centers for Disease Control and Prevention’s latest Autism and Developmental Disabilities Monitoring Network survey, Washington, D.C., U.S ...

Story Jan. 22 - Biogen: The neuro-focused biotech is making an undisclosed number of cuts to its research team as it prioritizes its preclinical pipeline and shifts resources to external ...